Table 3.
3A | ||||||||
All patients (N = 130) |
|
|
|
|
||||
|
ROC (95% CI) |
Cut point (ng/ml) |
Sensitivity (%) |
Specificity (%) |
|
|
|
|
uNGAL |
|
|
|
|
|
|
|
|
baseline |
0.78 (0.68 to 0.87) |
75 |
77 |
74 |
|
|
|
|
3 h |
0.80 (0.69 to 0.89) |
104 |
77 |
76 |
|
|
|
|
6 h |
0.85 (0.76 to 0.91) |
117 |
94 |
78 |
|
|
|
|
12 h |
0.82 (0.74 to 0.90) |
142 |
88 |
76 |
|
|
|
|
18 h |
0.84 (0.76 to 0.91) |
161 |
82 |
76 |
|
|
|
|
24 h |
0.86 (0.79 to 0.93) |
184 |
82 |
81 |
|
|
|
|
Delta of uNGAL |
|
|
|
|
|
|
|
|
0-3 h |
0.66 (0.49 to 0.79) |
22 |
85 |
78 |
|
|
|
|
0-6 h |
0.83 (0.75 to 0.92) |
45 |
88 |
80 |
|
|
|
|
0-12 h |
0.80 (0.72 to 0.89) |
71 |
88 |
79 |
|
|
|
|
0-18 h |
0.78 (0.67 to 0.90) |
77 |
82 |
73 |
|
|
|
|
0-24 h |
0.79 (0.67 to 0.91) |
71 |
77 |
74 |
|
|
|
|
3B | ||||||||
|
CKD stage III (N = 100) |
CKD stage IV (N = 30) |
||||||
|
ROC (95% CI) |
Cut point (ng/ml) |
Sensitivity (%) |
Specificity (%) |
ROC (95% CI) |
Cut point (ng/ml) |
Sensitivity (%) |
Specificity (%) |
uNGAL |
|
|
|
|
|
|
|
|
baseline |
0.72 (0.61 to 0.83) |
61 |
70 |
71 |
0.87 (0.73 to 1.0) |
84 |
86 |
73 |
3 h |
0.79 (0.65 to 0.93) |
108 |
80 |
78 |
0.88 (0.75 to 1.0) |
155 |
86 |
82 |
6 h |
0.82 (0.72 to 0.92) |
117 |
92 |
80 |
0.89 (0.80 to 1.0) |
207 |
86 |
86 |
12 h |
0.77 (0.67 to 0.88) |
142 |
84 |
75 |
0.86 (0.72 to 0.99) |
281 |
86 |
83 |
18 h |
0.81 (0.72 to 0.89) |
161 |
70 |
76 |
0.83 (0.68 to 0.97) |
285 |
83 |
78 |
24 h |
0.82 (0.74 to 0.92) |
184 |
78 |
81 |
0.88 (0.75 to 1.0) |
235 |
86 |
83 |
Delta of uNGAL |
|
|
|
|
|
|
|
|
0-3 h |
0.80 (0.64 to 0.96) |
24 |
90 |
78 |
0.75 (0.49 to 1.0) |
22 |
86 |
78 |
0-6 h |
0.82 (0.69 to 0.95) |
42 |
91 |
79 |
0.89 (0.77 to 1.0) |
54 |
100 |
87 |
0-12 h |
0.76 (0.64 to 0.88) |
65 |
82 |
77 |
0.88 (0.75 to 1.0) |
71 |
100 |
83 |
0-18 h |
0.80 (0.71 to 0.89) |
77 |
88 |
73 |
0.73 (0.47 to 1.0) |
102 |
86 |
83 |
0-24 h | 0.81 (0.70 to 0.91) | 61 | 80 | 74 | 0.73 (0.47 to 0.99) | 91 | 71 | 78 |